Molecular Mechanisms of Axonal Pathology in Alzheimer’s Disease
![a headshot of Dr. Cai](https://www.brightfocus.org/wp-content/uploads/2024/10/ADR_yifei_cai.png)
About the Research Project
Program
Award Type
Postdoctoral Fellowship
Award Amount
$200,000
Active Dates
July 01, 2021 - June 30, 2023
Grant ID
A2021003F
Mentor(s)
Jaime Grutzendler, MD, Yale University
Goals
Investigate the molecular and cellular mechanisms of axonal dystrophy formation in Alzheimer’s disease; examine reversibility of axonal dystrophy and whether this can restore normal axonal function. In Aim 1, I will study the proteins accumulated in axonal dystrophies in postmortem human AD brains by using proximity-labeling proteomic analysis, and uncover signaling pathways with potential relevance to axonal dystrophy formation and growth; in Aim 2, I will validate proteomic candidates identified in aim 1 in both postmortem human AD brains and AD-model mice; in Aim 3, I will examine the reversibility of axonal dystrophy by molecular manipulation of the PI3K/AKT/MTOR pathway or FDA approved drugs treatments in AD-model mice, and determine whether these improve axonal conduction in vivo.
Summary
Amyloid deposits in Alzheimer’s disease are surrounded by axons with abnormally enlarged bulbous structures. The Grutzendler lab has demonstrated that these structures severely affect axonal conduction of signals and that this may be correlated with memory loss in humans. The goal of this project is to investigate the molecular and cellular mechanisms involved in the formation of these bulbs. My ultimate goal is determining if reversing this pathology is possible, and if so whether this can restore normal axonal function.
Unique and Innovative
Using proximity labeling proteomics, this study may be the first time to isolate and identify the proteome of axonal dystrophy, one of the three neuropathologic hallmarks in Alzheimer’s disease. This study will allow us to study the molecular and cellular mechanisms govern the axonal dystrophy formation. Utilization of both postmortem human AD brain specimens and AD-model mice will provide insights into the axonal dystrophy pathology in a complementary way.
Foreseeable Benefits
Given the accumulating failures of anti-amyloid drugs in AD clinical trials, identifying the molecular pathways that can prevent axonal dystrophy formation and ameliorate axon conduction deficits may provide novel therapeutic targets for AD, independent of amyloid removal. We believe information derived from these studies will suggest novel therapeutic targets for ameliorating axonal pathology in AD and will become a valuable resource for the scientific community.
Grants
Related Grants
Alzheimer's Disease Research
Progranulin as a Potential Therapeutic Target for Alzheimer's Disease
Active Dates
July 01, 2024 - June 30, 2027
![a headshot of Dr. Nguyen](https://www.brightfocus.org/wp-content/uploads/2024/10/ADR_andrew_nguyen.png)
Principal Investigator
Andrew Nguyen, PhD
Alzheimer's Disease Research
Does Alzheimer’s Disease Accelerate Brain Aging?
Active Dates
July 01, 2024 - June 30, 2027
![a headshot of Dr. Llorens-Martin](https://www.brightfocus.org/wp-content/uploads/2024/10/ADR_maria_llorens-martin.png)
Principal Investigator
María Llorens-Martín, PhD
Alzheimer's Disease Research
Mechanisms of Inhibitory Neuron Vulnerability to Alzheimer’s Disease
Active Dates
July 01, 2024 - June 30, 2026
![a headshot of Dr. Zamponi](https://www.brightfocus.org/wp-content/uploads/2024/10/ADR_emiliano_zamponi.png)
Principal Investigator
Emiliano Zamponi, PhD